Niaspan buyers denied class cert
A federal judge in Pennsylvania has rejected a bid for class certification by end-purchasers of cholesterol medication Niaspan in their lawsuit against drugmakers AbbVie and Teva Pharmaceuticals.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10